logo
  

Harbour BioMed Collaborates With Moderna On Nucleic Acid-based Immunotherapies

Harbour BioMed said that its subsidiary, Nona Biosciences, has collaborated with Moderna Inc. (MRNA) to focus on discovering and developing nucleic acid-based immunotherapies for select oncology targets using Harbour's proprietary heavy chain only antibody discovery platform (HCAb).

Upon the execution of the agreement, Moderna will be granted an exclusive sub-licensable license to exploit a panel of sequences against multiple targets, derived from the Company's HCAb platform, to develop products using nucleic acids.

Moderna will assume full responsibility for all upcoming development, manufacturing, regulatory, and commercialization activities. Moderna would also be granted an option to obtain an exclusive sub-licensable license to exploit sequences against additional targets.

As per the deal, Nona Biosciences shall receive an upfront payment, and potential milestone payments based on pending achievement of certain regulatory, development, and sales milestones, and tiered royalties.

For More Such Health News, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Drug major Pfizer Inc. reported Tuesday higher earnings in its fourth quarter, above market estimates, and an all-time high revenues in its fiscal 2022. Meanwhile, the company projects sharply lower adjusted earnings and revenues in its fiscal 2023, below Wall Street estimates, reflecting projected decline for COVID-19 products. In pre-market activity on the NYSE, Pfizer shares were losing around Oil major Exxon Mobil Corp. (XOM) reported Tuesday that fourth-quarter net income was $12.75 billion or $3.09 per share, up from $8.87 million or $2.08 per share in the prior-year quarter. Excluding special items, adjusted earnings were $3.40 per share, compared to $2.05 per share in the prior-year... La Mirada, California-based Daiso California LLC is recalling certain Matsunaga Mini Shiruko Sand Biscuits citing undeclared soy, an allergen, the U.S. Food and Drug Administration said. The recall incolves Matsunaga Mini Shiruko Sand Biscuits with sku 4902773016966, packaged in four pink and cream bags chained together. Each individual serving is 25g for an entire product weight of 100g.
Follow RTT